STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13

Nature Communications

Volumn 5, Issue , 2014, Pages

  Zhang, Huiyuan ^a   Hu, Hongbo ^a   Greeley, Nathaniel ^a,b   Jin, Jin ^a   Matthews, Allison J ^a   Ohashi, Erika ^a   Caetano, Mauricio S ^a   Li, Haiyan S ^a   Wu, Xuefeng ^a   Mandal, Pijus K ^a   McMurray, John S ^a,b   Moghaddam, Seyed Javad ^a,b   Sun, Shao Cong ^a,b   Watowich, Stephanie S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE H3 LYSINE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR ETS 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN CONJUGATING ENZYME 13; UNCLASSIFIED DRUG; ETS1 PROTEIN, MOUSE; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; STAT3 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; UBC13 PROTEIN, MOUSE; UBIQUITIN CONJUGATING ENZYME;

CYTOLOGY; GENE EXPRESSION; IMMUNE RESPONSE; INHIBITION;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GENE; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; MALE; METABOLISM; PRIMARY CELL CULTURE;

ANIMALS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; NF-KAPPA B; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEIN C-ETS-1; RANK LIGAND; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION, GENETIC; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITINATION;

EID: 84922130866     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6798     Document Type: Article

References (41)

1. O?Shea, J. J. & Murray, P. J. Cytokine signaling modules in inflammatory responses. Immunity 28, 477-487 (2008).
2. Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49 (1999).
3. Melillo, J. A. et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J. Immunol. 184, 2638-2645 (2010).
4. Welte, T. et al. STAT3 deletion during hematopoiesis causes Crohn?s diseaselike pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl Acad. Sci. USA 100, 1879-1884 (2003).
5. Heimall, J., Freeman, A. & Holland, S. M. Pathogenesis of hyper IgE syndrome. Clin. Rev. Allergy Immunol. 38, 32-38 (2010).
6. Holland, S. M. et al. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357, 1608-1619 (2007).
7. Steward-Tharp, S. M. et al. A mouse model of HIES reveals pro and antiinflammatory functions of STAT3. Blood 123, 2978-2987 (2014).
8. Leung, D. Y. et al. Increased in vitro bone resorption by monocytes in the hyper-immunoglobulin E syndrome. J. Immunol. 140, 84-88 (1988).
9. Zhang, Z. et al. Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem. Biophys. Res. Commun. 328, 800-807 (2005).
10. Nefedova, Y. & Gabrilovich, D. I. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr. Cancer Drug Targets 7, 71-77 (2007).
11. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
12. Ben-Neriah, Y. & Karin, M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 12, 715-723 (2011).
13. Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999).
14. Deng, L. et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361 (2000).
15. Fukushima, T. et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc. Natl Acad. Sci. USA 104, 6371-6376 (2007).
16. Grivennikov, S. I. & Karin, M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11-19 (2010).
17. Duplomb, L. et al. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 149, 3688-3697 (2008).
18. Xing, Z. et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101, 311-320 (1998).
19. Tangye, S. G., Cook, M. C. & Fulcher, D. A. Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J. Immunol. 182, 21-28 (2009).
20. Wajant, H., Henkler, F. & Scheurich, P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell. Signal. 13, 389-400 (2001).
21. Shembade, N., Ma, A. & Harhaj, E. W. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327, 1135-1139 (2010).
22. Babon, J. J. et al. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J. Mol. Biol. 381, 928-940 (2008).
23. Murray, P. J. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc. Natl Acad. Sci. USA 102, 8686-8691 (2005).
24. Auzenne, E. J. et al. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J. Exp. Ther. Oncol. 10, 155-162 (2012).
25. Dore, L. C., Chlon, T. M., Brown, C. D., White, K. P. & Crispino, J. D. Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis. Blood 119, 3724-3733 (2012).
26. Lee, J. H. & Skalnik, D. G. Wdr82 is a C-terminal domain-binding protein that recruits the Setd1A Histone H3-Lys4 methyltransferase complex to transcription start sites of transcribed human genes. Mol. Cell. Biol. 28, 609-618 (2008).
27. El Kasmi, K. C. et al. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 177, 7880-7888 (2006).
28. Kortylewski, M. et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114-123 (2009).
29. Brocke-Heidrich, K. et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 25, 7297-7304 (2006).
30. Poli, V. et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13, 1189-1196 (1994).
31. Mauer, J. et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423-430 (2014).
32. Williams, L. M., Ricchetti, G., Sarma, U., Smallie, T. & Foxwell, B. M. Interleukin-10 suppression of myeloid cell activation - A continuing puzzle. Immunology 113, 281-292 (2004).
33. Yasukawa, H. et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4, 551-556 (2003).
34. Yang, X. P. et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12, 247-254 (2011).
35. Esashi, E. et al. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28, 509-520 (2008).
36. Taniguchi, K. & Karin, M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 26, 54-74 (2014).
37. Zhang, H. et al. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116, 2462-2471 (2010).
38. Yamamoto, M. et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat. Immunol. 7, 962-970 (2006).
39. Waterfield, M. R., Zhang, M., Norman, L. P. & Sun, S. C. NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol. Cell 11, 685-694 (2003).
40. Jin, W. et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J. Clin. Invest. 118, 1858-1866 (2008).
41. Hu, H. et al. Noncanonical NF-kappaB regulates inducible costimulator (ICOS) ligand expression and T follicular helper cell development. Proc. Natl Acad. Sci. USA 108, 12827-12832 (2011).